Idiopathic pulmonary fibrosis
Conditions
Interventions
Patients were treated with intravenous immunoglobulin (IVIG) at 0.4 g/kg/day for 5 consecutive days (5-day IVIG group)
Patients were treated with intravenous immunoglobulin (IVIG) at 0.4 g/kg/day onc
Sponsors
Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients with adequate oxygenation as evidenced by: 1) an arterial oxygen pressure (PaO2) of 80 Torr or more at rest and minimum saturation of peripheral oxygen (SpO2) of less than 90% in the 6 minutes walk test (6MWT), 2) PaO2 at rest of 70 Torr or more to less than 80 Torr or 3) PaO2 at rest of 60 Torr or more to less than 70 Torr and minimum SpO2 of 90 % or more in the 6MWT.
Exclusion criteria
Exclusion criteria: Coexisting or clinical suspicion of sarcoidosis, hypersensitivity pneumonitis, connective tissue diseases, pneumoconiosis, drug-induced pneumonitis, infectious disease, pregnancy, coexisting chronic obstructive pulmonary disease (COPD), bronchial asthma, bronchiectasis, neoplasm, severe cardiovascular disease, cerebrovascular disease, chronic kidney disease, or thromboembolism. Patients who were unable to undergo physiologic tests, unable to understand the protocol or provide written informed consent, or who were administered with 20 mg/day or more of predonisolone, immunosuppressive agents, antifibrotic agents, or immunoglobulin during the preceding 3 months
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in vital capacity | — |
Secondary
| Measure | Time frame |
|---|---|
| Changes in diffusion capacity of the lung for carbon monoxide (DLCO), 6-minute walk test, and high-resolution computed tomography (HRCT) findings | — |
Countries
Japan
Contacts
Public ContactNoriyuki Enomoto
Hamamatsu University School of Medicine Second Division, Department of Internal Medicine
Outcome results
None listed